FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Emanuel Escher

Research Profile

Chemicals & Drugs

Anatomy

COS Cells

Genes & Molecular Sequences

Amino Acid Sequences

Concepts & Ideas

Living Beings

Physiology

Mutagenesis, Site-Directed

Phenomena

Protein Binding

Co-author Network

Publications

TOP 3
Dany Fillion; Gaétan Guillemette; Pierre Lavigne; Richard Leduc; Jérôme Cabana; Emanuel Escher
Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode.
Philip E Boulais; Emanuel Escher; Richard Leduc
Analysis by substituted cysteine scanning mutagenesis of the fourth transmembrane domain of the CXCR4 receptor in its inactive and active state.
Jason Arsenault; Jérôme Cabana; Dany Fillion; Richard Leduc; Gaétan Guillemette; Pierre Lavigne; Emanuel Escher
Temperature dependent photolabeling of the human angiotensin II type 1 receptor reveals insights into its conformational landscape and its activation mechanism.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Emanuel Escher (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Dany Fillion; Gaétan Guillemette; Pierre Lavigne; Richard Leduc; Jérôme Cabana; Emanuel Escher
Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode.
The Journal of biological chemistry 2013;288(12):8187-97.
2013: Philip E Boulais; Emanuel Escher; Richard Leduc
Analysis by substituted cysteine scanning mutagenesis of the fourth transmembrane domain of the CXCR4 receptor in its inactive and active state.
Biochemical pharmacology 2013;85(4):541-50.
2010: Jason Arsenault; Jérôme Cabana; Dany Fillion; Richard Leduc; Gaétan Guillemette; Pierre Lavigne; Emanuel Escher
Temperature dependent photolabeling of the human angiotensin II type 1 receptor reveals insights into its conformational landscape and its activation mechanism.
Biochemical pharmacology 2010;80(7):990-9.
2010: Jason Arsenault; Julie Lehoux; Luc Lanthier; Jérôme Cabana; Gaëtan Guillemette; Pierre Lavigne; Richard Leduc; Emanuel Escher
A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Pharmacogenetics and genomics 2010;20(6):377-88.
2010: Dany Fillion; Guillaume Lemieux; Luta Luse Basambombo; Pierre Lavigne; Gaétan Guillemette; Richard Leduc; Emanuel Escher
The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1.
Journal of medicinal chemistry 2010;53(5):2063-75.
2010: Liping Yan; Brian J Holleran; Pierre Lavigne; Emanuel Escher; Gaétan Guillemette; Richard Leduc
Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis.
The Journal of biological chemistry 2010;285(4):2284-93.
2009: Philip E Boulais; Dominic Dulude; Jérôme Cabana; Nikolaus Heveker; Emanuel Escher; Pierre Lavigne; Richard Leduc
Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site.
Biochemical pharmacology 2009;78(11):1382-90.
2009: Ivana Domazet; Stéphane S Martin; Brian J Holleran; Marie-Eve Morin; Patrick Lacasse; Pierre Lavigne; Emanuel Escher; Richard Leduc; Gaétan Guillemette
The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation.
The Journal of biological chemistry 2009;284(46):31953-61.
2009: Martin Clément; Jérôme Cabana; Brian J Holleran; Richard Leduc; Gaétan Guillemette; Pierre Lavigne; Emanuel Escher
Activation induces structural changes in the liganded angiotensin II type 1 receptor.
The Journal of biological chemistry 2009;284(39):26603-12.
2009: Ivana Domazet; Brian J Holleran; Stéphane S Martin; Pierre Lavigne; Richard Leduc; Emanuel Escher; Gaétan Guillemette
The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation.
The Journal of biological chemistry 2009;284(18):11922-9.
2009: Brian J Holleran; Ivana Domazet; Marie-Eve Beaulieu; Li Ping Yan; Gaétan Guillemette; Pierre Lavigne; Emanuel Escher; Richard Leduc
Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor.
Biochemical pharmacology 2009;77(8):1374-82.
2009: Vincent Chabot; Charles M Cuerrier; Emanuel Escher; Vincent Aimez; michel Grandbois; Paul Charette
Biosensing based on surface plasmon resonance and living cells.
Biosensors & bioelectronics 2009;24(6):1667-73.
2009: Beata Jastrzebska; Rejean Lebel; Oliver J McIntyre; Benoit Paquette; Witold Neugebauer; Emanuel Escher; Martin Lepage
Monitoring of MMPs activity in vivo, non-invasively, using solubility switchable MRI contrast agent.
Advances in experimental medicine and biology 2009;611():453-4.
2009: Ewa Wieczerzak; Raymond Hame; Vincent Chabot; Vincent Aimez; Paul Charette; michel Grandbois; Emanuel Escher
Monitoring of native chemical ligation by surface plasmon resonance.
Advances in experimental medicine and biology 2009;611():427-9.
2009: Martin Clément; Gaétan Guillemette; Richard Leduc; Emanuel Escher
Structural changes in the binding pocket of the liganded angiotensin II receptor AT1 during activation.
Advances in experimental medicine and biology 2009;611():341-2.
2009: Julie Arsenault; M P La-Haye Renaud; Martin Clément; Dany Fillion; Gaétan Guillemette; Richard Leduc; Pierre Lavigne; Emanuel Escher
Temperature-induced ligand contact point variations of the hAT1 receptor and of the constitutively active mutant N111G-hAT1.
Advances in experimental medicine and biology 2009;611():339-40.
2009: Dany Fillion; Gaétan Guillemette; Richard Leduc; Emanuel Escher
Photoprobe peptides to map the interactions of angiotensin II with its receptor AT1.
Advances in experimental medicine and biology 2009;611():329-30.
2008: Réjean Lebel; Beata Jastrzebska; Hélène Therriault; Marie-Michèle Cournoyer; J Oliver McIntyre; Emanuel Escher; Witold Neugebauer; Benoit Paquette; Martin Lepage
Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2008;60(5):1056-65.
2008: Christophe D Proulx; Brian J Holleran; Antony A Boucard; Emanuel Escher; Gaétan Guillemette; Richard Leduc
Mutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptor.
Molecular pharmacology 2008;74(3):552-61.
2008: Christophe D Proulx; Brian J Holleran; Pierre Lavigne; Emanuel Escher; Gaétan Guillemette; Richard Leduc
Biological properties and functional determinants of the urotensin II receptor.
Peptides 2008;29(5):691-9.
2008: Ewa Wieczerzak; Raymond Hamel; Vincent Chabot; Vincent Aimez; michel Grandbois; Paul Charette; Emanuel Escher
Monitoring of native chemical ligation on solid substrate by surface plasmon resonance.
Biopolymers 2008;90(3):415-20.
2008: Patrice C Leclerc; Christophe D Proulx; Guillaume Arguin; Simon Bélanger; Fernand Gobeil; Emanuel Escher; Richard Leduc; Gaétan Guillemette
Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II.
American journal of hypertension 2008;21(1):67-71.
2007: Julie Arsenault; M P La Haye Renaud; M Clément; Dany Fillion; Gaétan Guillemette; Richard Leduc; Pierre Lavigne; Emanuel Escher
Temperature-dependent variations of ligand-receptor contact points in hAT(1).
Journal of peptide science : an official publication of the European Peptide Society 2007;13(9):575-80.
2007: Stéphane S Martin; Brian J Holleran; Emanuel Escher; Gaétan Guillemette; Richard Leduc
Activation of the angiotensin II type 1 receptor leads to movement of the sixth transmembrane domain: analysis by the substituted cysteine accessibility method.
Molecular pharmacology 2007;72(1):182-90.
2007: Pierre Cloutier; C Sicard-Roselli; Emanuel Escher; Léon Sanche
Low-energy (3-24 eV) electron damage to the peptide backbone.
The journal of physical chemistry. B 2007;111(7):1620-4.
2007: Brian J Holleran; Marie-Eve Beaulieu; Christophe D Proulx; Pierre Lavigne; Emanuel Escher; Richard Leduc
Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.
The Biochemical journal 2007;402(1):51-61.
2006: Martin Clément; Emanuel Escher
[The methionine proximity assay: an approach to glean receptor structures].
Médecine sciences : M/S 2006;22(12):1017-8.
2006: Patrice C Leclerc; Pascal M Lanctot; Mannix Auger-Messier; Emanuel Escher; Richard Leduc; Gaétan Guillemette
S-nitrosylation of cysteine 289 of the AT1 receptor decreases its binding affinity for angiotensin II.
British journal of pharmacology 2006;148(3):306-13.
2006: Dany Fillion; Maud Deraët; Brian J Holleran; Emanuel Escher
Stereospecific synthesis of a carbene-generating angiotensin II analogue for comparative photoaffinity labeling: improved incorporation and absence of methionine selectivity.
Journal of medicinal chemistry 2006;49(7):2200-9.
2006: Pascal M Lanctôt; Patrice C Leclerc; Emanuel Escher; Gaétan Guillemette; Richard Leduc
Role of N-glycan-dependent quality control in the cell-surface expression of the AT1 receptor.
Biochemical and biophysical research communications 2006;340(2):395-402.
2006: Tommy Gagnon; Dany Fillion; Marie-Reine Lefebvre; Emanuel Escher
Synthesis of an agonistic, difluoro-azido photolabel of angiotensin II and labeling of the AT1 receptor: transmembrane domains 3, 6, and 7 form the ligand-binding pocket.
Journal of receptor and signal transduction research 2006;26(5-6):435-51.
2006: Martin Clément; Caroline Chamberland; Jacqueline Pérodin; Richard Leduc; Gaétan Guillemette; Emanuel Escher
The active and the inactive form of the hAT1 receptor have an identical ligand-binding environment: an MPA study on a constitutively active angiotensin II receptor mutant.
Journal of receptor and signal transduction research 2006;26(5-6):417-33.
2005: Pascal M Lanctot; Patrice C Leclerc; Martin Clément; Mannix Auger-Messier; Emanuel Escher; Richard Leduc; Gaétan Guillemette
Importance of N-glycosylation positioning for cell-surface expression, targeting, affinity and quality control of the human AT1 receptor.
The Biochemical journal 2005;390(Pt 1):367-76.
2005: Mannix Auger-Messier; Eric S Turgeon; Richard Leduc; Emanuel Escher; Gaétan Guillemette
The constitutively active N111G-AT1 receptor for angiotensin II modifies the morphology and cytoskeletal organization of HEK-293 cells.
Experimental cell research 2005;308(1):188-95.
2005: Martin Clément; Stéphane S Martin; Marie-Eve Beaulieu; Caroline Chamberland; Pierre Lavigne; Richard Leduc; Gaétan Guillemette; Emanuel Escher
Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assay.
The Journal of biological chemistry 2005;280(29):27121-9.
2005: Christophe D Proulx; May Simaan; Emanuel Escher; Stephane Laporte; Gaétan Guillemette; Richard Leduc
Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization.
The Biochemical journal 2005;385(Pt 1):115-23.
2004: Stéphane S Martin; Antony A Boucard; Martin Clément; Emanuel Escher; Richard Leduc; Gaétan Guillemette
Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis.
The Journal of biological chemistry 2004;279(49):51415-23.
2004: Mannix Auger-Messier; Guillaume Arguin; Benoit Chaloux; Richard Leduc; Emanuel Escher; Gaétan Guillemette
Down-regulation of inositol 1,4,5-trisphosphate receptor in cells stably expressing the constitutively active angiotensin II N111G-AT(1) receptor.
Molecular endocrinology (Baltimore, Md.) 2004;18(12):2967-80.
2003: Mannix Auger-Messier; Martin Clement; Pascal M Lanctot; Patrice C Leclerc; Richard Leduc; Emanuel Escher; Gaétan Guillemette
The constitutively active N111G-AT1 receptor for angiotensin II maintains a high affinity conformation despite being uncoupled from its cognate G protein Gq/11alpha.
Endocrinology 2003;144(12):5277-84.
2003: Antony A Boucard; Marise Roy; Marie-Eve Beaulieu; Pierre Lavigne; Emanuel Escher; Gaétan Guillemette; Richard Leduc
Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocket.
The Journal of biological chemistry 2003;278(38):36628-36.
2003: Antony A Boucard; Simon Sauvé; Gaétan Guillemette; Emanuel Escher; Richard Leduc
Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.
The Biochemical journal 2003;370(Pt 3):829-38.
2002: Jacqueline Pérodin; Maud Deraët; Mannix Auger-Messier; Antony A Boucard; Lenka Rihakova; Marie-Eve Beaulieu; Pierre Lavigne; Jean-Luc Parent; Gaétan Guillemette; Richard Leduc; Emanuel Escher
Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptor.
Biochemistry 2002;41(48):14348-56.
2002: Patrice C Leclerc; Mannix Auger-Messier; Pascal M Lanctot; Emanuel Escher; Richard Leduc; Gaétan Guillemette
A polyaromatic caveolin-binding-like motif in the cytoplasmic tail of the type 1 receptor for angiotensin II plays an important role in receptor trafficking and signaling.
Endocrinology 2002;143(12):4702-10.
2002: Dung Pham; Arco Y Jeng; Sylvain Plante; Emanuel Escher; Bruno Battistini
Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery.
Canadian journal of physiology and pharmacology 2002;80(5):450-7.
2002: Maud Deraët; Lenka Rihakova; Antony A Boucard; J Pèrodin; Simon Sauvé; Axel P Mathieu; Gaétan Guillemette; Richard Leduc; Pierre Lavigne; Emanuel Escher
Angiotensin II is bound to both receptors AT1 and AT2, parallel to the transmembrane domains and in an extended form.
Canadian journal of physiology and pharmacology 2002;80(5):418-25.
2002: Lenka Rihakova; Maud Deraët; Mannix Auger-Messier; Jacqueline Pérodin; Antony A Boucard; Gaétan Guillemette; Richard Leduc; Pierre Lavigne; Emanuel Escher
Methionine proximity assay, a novel method for exploring peptide ligand-receptor interaction.
Journal of receptor and signal transduction research 2002;22(1-4):297-313.
2001: Jacqueline Pérodin; Antony A Boucard; Richard Leduc; Emanuel Escher; Gaétan Guillemette
Assays for radiolabel-photoaffinity labeling of Angiotensin receptors.
Methods in molecular medicine 2001;51():297-303.
2000: Dung Pham; AY Jeng; Emanuel Escher; Pierre Sirois; Bruno Battistini
Effects of a selective neutral endopeptidase and a nonselective neutral endopeptidase/endothelin-converting enzyme inhibitor on lipopolysaccharide-induced endotoxaemia in anaesthetized Sprague-Dawley rats.
Journal of cardiovascular pharmacology 2000;36(5 Suppl 1):S362-6.
2000: Antony A Boucard; B C Wilkes; Stephane Laporte; Emanuel Escher; Gaétan Guillemette; Richard Leduc
Photolabeling identifies position 172 of the human AT(1) receptor as a ligand contact point: receptor-bound angiotensin II adopts an extended structure.
Biochemistry 2000;39(32):9662-70.
2000: M J Gosselin; Patrice C Leclerc; Mannix Auger-Messier; Gaétan Guillemette; Emanuel Escher; Richard Leduc
Molecular cloning of a ferret angiotensin II AT(1) receptor reveals the importance of position 163 for Losartan binding.
Biochimica et biophysica acta 2000;1497(1):94-102.
2000: Jacqueline Pérodin; R Bouley; Emanuel Escher; N Assimomytis; Vassiliki Magafa; Evy Manessi-Zoupa; D Theodoropoulos; Paul Cordopatis
Angiotensin II analogues with sulphur-containing side-chains in position 5. A structure-activity relationship study.
Arzneimittel-Forschung 2000;50(6):526-9.
2000: M Poitras; SN Poirier; Karina Laflamme; M Simoneau; Emanuel Escher; Gaétan Guillemette
Different populations of inositol 1,4,5-trisphosphate receptors expressed in the bovine adrenal cortex.
Receptors & channels 2000;7(1):41-52.
1999: P M Lanctôt; Patrice C Leclerc; Emanuel Escher; Richard Leduc; Gaétan Guillemette
Role of N-glycosylation in the expression and functional properties of human AT1 receptor.
Biochemistry 1999;38(27):8621-7.
1999: Stephane Laporte; Antony A Boucard; Guy Servant; Gaétan Guillemette; Richard Leduc; Emanuel Escher
Determination of peptide contact points in the human angiotensin II type I receptor (AT1) with photosensitive analogs of angiotensin II.
Molecular endocrinology (Baltimore, Md.) 1999;13(4):578-86.
1999: L Chrétien; Stephane Laporte; Emanuel Escher; Richard Leduc; Gaétan Guillemette
The bradykinin B2 receptor couples less efficiently than the angiotensin AT1 receptor to the G protein Gq in transiently transfected COS-7 cells.
Receptors & channels 1999;6(6):425-33.
1998: SG Bernier; J M Bellemare; Emanuel Escher; Gaétan Guillemette
Characterization of AT4 receptor from bovine aortic endothelium with photosensitive analogues of angiotensin IV.
Biochemistry 1998;37(12):4280-7.
1998: R Bouley; Jacqueline Pérodin; H Plante; Lenka Rihakova; SG Bernier; L Maletínská; Gaétan Guillemette; Emanuel Escher
N- and C-terminal structure-activity study of angiotensin II on the angiotensin AT2 receptor.
European journal of pharmacology 1998;343(2-3):323-31.
1998: Guy Servant; Emanuel Escher; Gaétan Guillemette
The angiotensin II binding site on Mycoplasma hyorhynis is structurally distinct from mammalian AT1 and AT2 receptors.
Regulatory peptides 1998;73(1):35-41.
1998: Stephane Laporte; S F Roy; Emanuel Escher; Gaétan Guillemette; Richard Leduc
Essential role of leucine222 in mediating signal transduction of the human angiotensin II type 1 receptor.
Receptors & channels 1998;5(2):103-12.
1997: L Maletínská; Witold Neugebauer; Jacqueline Pérodin; Marie-Reine Lefebvre; Emanuel Escher
Angiotensin analogues palmitoylated in positions 1 and 4.
Journal of medicinal chemistry 1997;40(20):3271-9.
1997: L Chrétien; Stephane Laporte; Emanuel Escher; Richard Leduc; Gaétan Guillemette
Use of LiCl in phospholipase C assays masks the impaired functionality of a mutant angiotensin II receptor.
Cellular signalling 1997;9(5):379-82.
1997: S F Roy; Stephane Laporte; Emanuel Escher; Richard Leduc; Gaétan Guillemette
Epitope tagging and immunoreactivity of the human angiotensin II type 1 receptor.
Canadian journal of physiology and pharmacology 1997;75(6):690-5.
1997: R Bouley; M Gosselin; H Plante; Guy Servant; Jacqueline Pérodin; M Arcand; Gaétan Guillemette; Emanuel Escher
Characterization of a specific binding site for angiotensin II in chicken liver.
Canadian journal of physiology and pharmacology 1997;75(6):568-75.
1997: Guy Servant; Stephane Laporte; Richard Leduc; Emanuel Escher; Gaétan Guillemette
Identification of angiotensin II-binding domains in the rat AT2 receptor with photolabile angiotensin analogs.
The Journal of biological chemistry 1997;272(13):8653-9.
1996: D Barbeau; R Bouley; Emanuel Escher
Molecular weight determination of the hepatic vasopressin receptor with a high-affinity photoprobe.
International journal of peptide and protein research 1996;48(4):364-73.
1996: Jean-Luc Parent; C L Gouill; Emanuel Escher; Marek Rola-Pleszczynski; J Staková
Identification of transmembrane domain residues determinant in the structure-function relationship of the human platelet-activating factor receptor by site-directed mutagenesis.
The Journal of biological chemistry 1996;271(38):23298-303.
1996: W J Zhang; G V Nikiforovich; Jacqueline Pérodin; D E Richard; Emanuel Escher; G R Marshall
Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.
Journal of medicinal chemistry 1996;39(14):2738-44.
1996: D Pham; Stephane Laporte; Jacqueline Pérodin; R Bourgeois; Emanuel Escher
What can angiotensin antagonists do that converting-enzyme inhibition can't: the case of post-angioplastic restenosis.
Canadian journal of physiology and pharmacology 1996;74(7):867-77.
1996: Jacqueline Pérodin; R Bossé; S Gagnon; L M Zhou; R Bouley; Richard Leduc; Emanuel Escher
Structure-activity relationship of the agonist-antagonist transition on the type 1 angiotensin II receptor; the search for inverse agonists.
Advances in experimental medicine and biology 1996;396():131-43.
1996: Stephane Laporte; Guy Servant; DE Richard; Emanuel Escher; Gaétan Guillemette; Richard Leduc
The tyrosine within the NPXnY motif of the human angiotensin II type 1 receptor is involved in mediating signal transduction but is not essential for internalization.
Molecular pharmacology 1996;49(1):89-95.
1996: Guy Servant; D T Dudley; Emanuel Escher; Gaétan Guillemette
Analysis of the role of N-glycosylation in cell-surface expression and binding properties of angiotensin II type-2 receptor of rat pheochromocytoma cells.
The Biochemical journal 1996;313 ( Pt 1)():297-304.
1994: Paul Cordopatis; E Manessi-Zoupa; D Theodoropoulos; R Bossé; R Bouley; S Gagnon; Emanuel Escher
Methylation in positions 1 and 7 of angiotensin II. A structure-activity relationship study.
International journal of peptide and protein research 1994;44(4):320-4.
1994: P Dagenais; B Desprez; J Albert; Emanuel Escher
Direct covalent attachment of small peptide antigens to enzyme-linked immunosorbent assay plates using radiation and carbodiimide activation.
Analytical biochemistry 1994;222(1):149-55.
1994: Guy Servant; D T Dudley; Emanuel Escher; Gaétan Guillemette
The marked disparity between the sizes of angiotensin type 2 receptors from different tissues is related to different degrees of N-glycosylation.
Molecular pharmacology 1994;45(6):1112-8.
1993: M C Paré; S Maltais; Emanuel Escher
The neurogenic origin of hypertension in SHR may be mediated by angiotensin II through a receptor different from AT1 and AT2.
Regulatory peptides 1993;47(1):81-6.
1993: Guy Servant; Guylain Boulay; R Bossé; Emanuel Escher; Gaétan Guillemette
Photoaffinity labeling of subtype 2 angiotensin receptor of human myometrium.
Molecular pharmacology 1993;43(5):677-83.
1993: R Bossé; Guy Servant; L M Zhou; Guylain Boulay; Gaétan Guillemette; Emanuel Escher
Sar1-p-benzoylphenylalanine-angiotensin, a new photoaffinity probe for selective labeling of the type 2 angiotensin receptor.
Regulatory peptides 1993;44(2):215-23.
1993: P Dagenais; Emanuel Escher
Anti-angiotensin antibodies cross-reactive with nonpeptide angiotensin antagonists as angiotensin receptor model.
Regulatory peptides 1993;44(2):239-47.
1992: Stephane Laporte; Emanuel Escher
Neointima formation after vascular injury is angiotensin II mediated.
Biochemical and biophysical research communications 1992;187(3):1510-6.
1992: Guylain Boulay; Guy Servant; T T Luong; Emanuel Escher; Gaétan Guillemette
Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa.
Molecular pharmacology 1992;41(4):809-15.
1992: D Barbeau; S Guay; W Neugebauer; Emanuel Escher
Preparation and biological activities of potential vasopressin photoaffinity labels.
Journal of medicinal chemistry 1992;35(1):151-7.
1992: Gilles Guillon; D Barbeau; W Neugebauer; S Guay; Lyne Bilodeau; Marie-Noëlle Balestre; Nicole Gallo-Payet; Emanuel Escher
Fluorescent peptide hormones: development of high affinity vasopressin analogues.
Peptides 1992;13(1):7-11.
1990: R Bossé; M Gerold; W Fischli; M Holck; Emanuel Escher
An angiotensin with prolonged action and blood pressure--lowering properties.
Journal of cardiovascular pharmacology 1990;16 Suppl 4():S50-5.
1989: Gaétan Guillemette; Guylain Boulay; S Gagnon; Roger Bosse; Emanuel Escher
The peptide encoded by angiotensin II complementary RNA does not interfere with angiotensin II action.
The Biochemical journal 1989;261(1):309.
1989: Sylvain Bélisle; A Petit; D Bellabarba; Emanuel Escher; Jean-Guy LeHoux; Nicole Gallo-Payet
Ca2+, but not membrane lipid hydrolysis, mediates human chorionic gonadotropin production by luteinizing hormone-releasing hormone in human term placenta.
The Journal of clinical endocrinology and metabolism 1989;69(1):117-21.
1989: M Holck; R Bossé; W Fischli; H Gerold; Emanuel Escher
An angiotensin II antagonist with strongly prolonged action.
Biochemical and biophysical research communications 1989;160(3):1350-6.
1988: W Neugebauer; P Elliott; A Claudio Cuello; Emanuel Escher
Synthesis and immunological evaluation of N-terminal, noncrossreactive tachykinin antigens.
Journal of medicinal chemistry 1988;31(10):1907-10.
1988: Emanuel Escher
Photoaffinity labeling of angiotensin II and bradykinin receptors.
Pharmacology & therapeutics 1988;37(1):37-55.
1988: Emanuel Escher; Z Mackiewicz; G Lagacé; Jean-Guy LeHoux; Nicole Gallo-Payet; D Bellabarba; Sylvain Bélisle
Human placental LHRH receptor: agonist and antagonist labeling produces differences in the size of the non-denatured, solubilized receptor.
Journal of receptor research 1988;8(1-4):391-405.
1985: D Theodoropoulos; C Poulos; Dimitrios Gatos; Paul Cordopatis; Emanuel Escher; J Mizrahi; D Regoli; D Dalietos; A Furst; T D Lee
Conformationally restricted C-terminal peptides of substance P. Synthesis, mass spectral analysis and pharmacological properties.
Journal of medicinal chemistry 1985;28(10):1536-9.
1982: Emanuel Escher; R Couture; C Poulos; N Pinas; J Mizrahi; D Theodoropoulos; D Regoli
Structure-activity studies on the C-terminal amide of substance P.
Journal of medicinal chemistry 1982;25(11):1317-21.
1981: Paul Cordopatis; D Theodoropoulos; G Guillemette; Emanuel Escher
Studies on position 1 of angiotensin II: effects on affinity and duration of action from alkyl amide substitution.
Journal of medicinal chemistry 1981;24(2):209-11.